Intrexon Corp. (NYSE:XON) shot up 2.9% on Wednesday . The stock traded as high as $29.50 and last traded at $29.42, with a volume of 1,262,217 shares trading hands. The stock had previously closed at $28.58.

Several research analysts recently commented on the stock. Griffin Securities reaffirmed a “buy” rating and issued a $55.00 price target on shares of Intrexon Corp. in a research note on Tuesday. Zacks Investment Research downgraded shares of Intrexon Corp. from a “buy” rating to a “hold” rating in a research note on Friday, August 12th. Vetr raised shares of Intrexon Corp. from a “hold” rating to a “strong-buy” rating and set a $33.69 price target on the stock in a research note on Wednesday, August 3rd. JMP Securities reaffirmed a “buy” rating on shares of Intrexon Corp. in a research note on Sunday, July 17th. Finally, Wunderlich reaffirmed a “buy” rating and issued a $50.00 price target on shares of Intrexon Corp. in a research note on Thursday, July 7th. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Intrexon Corp. currently has a consensus rating of “Buy” and a consensus price target of $41.71.

The firm’s market cap is $3.47 billion. The company’s 50-day moving average price is $26.30 and its 200-day moving average price is $29.76.

Intrexon Corp. (NYSE:XON) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.16. During the same quarter last year, the firm posted ($0.37) earnings per share. The firm had revenue of $52.50 million for the quarter, compared to analysts’ expectations of $53.78 million. The company’s revenue was up 17.0% on a year-over-year basis. On average, analysts expect that Intrexon Corp. will post ($1.35) earnings per share for the current fiscal year.

Several hedge funds and institutional investors have recently made changes to their positions in XON. Dimensional Fund Advisors LP boosted its position in shares of Intrexon Corp. by 3.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 141,851 shares of the company’s stock valued at $4,278,000 after buying an additional 4,854 shares during the last quarter. Trexquant Investment LP purchased a new position in shares of Intrexon Corp. during the fourth quarter valued at $2,590,000. Bank of Montreal Can boosted its position in shares of Intrexon Corp. by 16.8% in the fourth quarter. Bank of Montreal Can now owns 40,010 shares of the company’s stock valued at $1,207,000 after buying an additional 5,742 shares during the last quarter. State of Wisconsin Investment Board boosted its position in shares of Intrexon Corp. by 2.5% in the fourth quarter. State of Wisconsin Investment Board now owns 35,410 shares of the company’s stock valued at $1,068,000 after buying an additional 880 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Intrexon Corp. by 6.7% in the fourth quarter. Rhumbline Advisers now owns 46,016 shares of the company’s stock valued at $1,387,000 after buying an additional 2,890 shares during the last quarter.

Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.